

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

ANNOUNCEMENT ON RESIGNATION AND APPOINTMENT OF INDEPENDENT DIRECTORS

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

1. Resignation of Independent Director

On 13 October 2023, the Board received the resignation letter of Mr. Zhu Haifeng (朱海峰) (“**Mr. Zhu**”), pursuant to which Mr. Zhu gave notice of his resignation as an independent director of the Company, as well as chairman of the Remuneration Committee, and a member of each of the Audit Committee, the Nomination Committee, and the Strategy Committee of the Company due to personal reasons (the “**Resignation**”). Following the Resignation, Mr. Zhu no longer holds any position in the Company.

In accordance with relevant provisions including the *Administrative Measures for Independent Directors of Listed Companies* (《上市公司独立董事管理办法》) issued by the China Securities Regulatory Commission, the *Rules Governing the Listing of Securities on Shanghai Stock Exchange* (《上海证券交易所股票上市规则》) issued by the Shanghai Stock Exchange (the “**SSE**”) (the “**SSE Listing Rules**”), the *Guidelines No.1 of the Shanghai Stock Exchange for Self-Regulation of Listed Companies - Standardised Operations* (《上海证券交易所上市公司自律监管指引第1号 - 规范运作》) issued by the SSE (the “**Guidelines No. 1**”), as well as the Articles of Association of the Company, as the Resignation will result in the number of independent directors of the Company to be less than one-third of the members of the Board, the Resignation shall take effect upon the appointment of a new independent director at a general meeting of the Company. Before the newly appointed independent director takes office, Mr. Zhu shall continue to perform his duties as an independent director and chairman/ member of the board committees of the Company in accordance with relevant laws and regulations. The Company will carry out the necessary procedures for the appointment of an independent director to fill the vacancy as soon as possible in accordance with the relevant provisions.

The Company would like to express its sincere gratitude to Mr. Zhu for his outstanding contribution to the development of the Company during his tenure as an independent director of the Company.

2. Appointment of Independent Director

To ensure the proper functioning of the Board, the Company had, on 13 October 2023, duly convened its 7th Board meeting for the financial year ending 31 December 2023 by means of live meeting and telephone conference in accordance with relevant provisions including the applicable Companies Law, Securities Law, the SSE Listing Rules and the Guidelines No. 1, as well as the Articles of Association of the Company, and upon review by the Nomination

Committee of the Company, the Board approved the resolution relating to the proposed appointment of Mr. Yeo Guat Kwang (杨木光) (“**Mr. Yeo**”) as an independent director of the Company (the “**Proposed Appointment**”). Mr. Yeo’s term of office shall commence from the date on which the Proposed Appointment is approved by shareholders of the Company at a general meeting of the Company and continue until the expiry of the term of office of the current Board which is on 10 December 2024. The independent directors of the Company for the time being agreed with the Proposed Appointment.

As at the date of this announcement, Mr. Yeo has not undergone the pre-appointment training for independent directors of a listed company on the SSE. However, he has undertaken to attend the upcoming session of pre-appointment training for independent directors of a listed company on the SSE and obtain the requisite training certificate in due course. Shareholder of the Company should note that the relevant materials of Mr. Yeo as a candidate standing for election as an independent director of the Company are still subject to the review and approval by the SSE, and the Proposed Appointment shall be tabled for shareholders’ approval at a general meeting of the Company.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
13 October 2023